People
BioSpace recently spoke with Dr. James Garner, CEO of Kazia Therapeutics, an oncology company that is focused on the development of cancer drugs.
Two new companies exploded onto the scene this morning, backed by significant financing that will be used to develop treatments for a wide range of diseases.
After months of urging the public to wear masks and facial coverings to help stop infected people from spreading COVID-19, the Centers for Disease Control and Prevention now states in newly released guidance that masks also protected the mask wearer from being infected.
San Francisco-based Vir Biotechnology and its chief executive officer, George Scangos, believe it has a terrific antibody therapy against SARS-CoV-2, the virus that causes COVID-19. But is it too late to the game?
This model has the benefit of giving companies direct oversight of their in vivo studies, allowing them to move faster while operationalizing every dollar of their seed financing.
Several states have pledged to review COVID-19 vaccines themselves, after FDA emergency use authorizations, to ensure safety and efficacy. A robust review, however, is unlikely.
Talaris Chief Executive Officer Scott Requadt sees FCR001, the company’s investigational cell therapy, as a potential pipeline in a product (an experimental treatment that could have multiple uses across a number of indications).
President-elect Joe Biden hit the ground running this morning with the announcement of his transition team’s COVID-19 advisory board.
According to recent polls, less than half of Americans trust pharmaceutical companies. In fact, only 42% of respondents say they have any trust in pharma, with a paltry 6% having a great deal.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
PRESS RELEASES